Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Cardiovascular Cancer Blood & Coagulation Disorders

US FDA highlights serious skin reactions with Revlimid

This article was originally published in Scrip

Executive Summary

The latest issue of the USFDA's Drug Safety Newsletter (Summer 2008) reviews 14 postmarketing reports of serious skin reactions possibly linked to Celgene's thalidomide analogue, Revlimid (lenalidomide), from the time of the product's US approval in December 2005 until January 2008. They include reports of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and erythema multiforme.

Table

View full table

Topics

Related Companies

Tags:
Cardiovascular Cancer Blood & Coagulation Disorders
Latest Headlines

Merck Investors Keeping A Close Watch On Winrevair Uptake

‘It’s Not About Me’ – AstraZeneca’s Soriot Says His Pay Rise Will Help European Pharma

Executives On The Move: Three New CEOs Among This Week's Changes

Sanofi To Pursue Smart M&A Pacts And Stick With Early-Stage Oncology R&D

See All
UsernamePublicRestriction

Register

SC030349

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By